한국형 양극성 장애 약물치료 알고리듬:개정 및 향후 방향Korean Medication Algorithm for Bipolar Disorder:Revision and Further Suggestion
- Authors
- 조현상; 박원명; 전덕인; 민경준; 윤보현; 신영철; 권준수; 김찬형
- Issue Date
- 2005
- Publisher
- 대한정신약물학회
- Keywords
- 양극성 장애; 한국형 약물치료 알고리듬; 알고리듬 개정; Bipolar disorder; Korean medication algorithm; Revision
- Citation
- 대한정신약물학회지, v.16, no.6, pp 433 - 442
- Pages
- 10
- Journal Title
- 대한정신약물학회지
- Volume
- 16
- Number
- 6
- Start Page
- 433
- End Page
- 442
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/29439
- ISSN
- 1017-5717
2092-5700
- Abstract
- The algorithms and guidelines are a synthesis of current scientific evidences with clinical issues of safety and tolerability. It is inevitable that pharmacological strategies of psychiatric treatment have to be based on evidence-based medicine. The first Korean Medication Algorithm for Bipolar Disorder was developed from the information and opinions gathered by wide surveys to Korean psychiatrists and then, in the first time, its feasibility study was done. The problems on appropriateness of the shift of step, full education of algorithm administration and procedure before implementation, and easy applicability of measuring scales were found. These problems must be fully considered for algorithm implementation in the near future. Rapid updates on new evidences of therapeutic effects of drugs and recent trends of diagnostic concepts about bipolar disorder may justify revision of the medication algorithm. Especially, addition of widespread use of novel antipsychotics in all phases of illness, evidences of new anticonvulsants' effects, and change of strategies in the acute depression and maintenance treatments will have to be considered. Moreover, modification of questionnaire for algorithm revision will be needed in the aspect of easy implementation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.